Citi keeps Buy rating for Chugai Pharmaceutical stock at JPY 11,100.00

Published on 10/09/2026 at 12:24 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Second-quarter revenue hit JPY 341.58 billion, up 17.80 percent. Chugai Pharmaceutical stock costs EUR 33.90 after EUR 34.33 on October 9, 2026.

Key points in brief

Citi maintained a Buy rating and set a JPY 11,100.00 price target on October 7, 2026.
Chugai Pharmaceutical reported second-quarter revenue of JPY 341.58 billion, up 17.80 percent.
The Lang & Schwarz quote was EUR 33.90 on October 9, 2026, down 1.25 percent versus EUR 34.33.
Chugai's next fiscal 2026 third-quarter results are scheduled for October 27, 2026.

Chugai Pharmaceutical, JP3519400000, Illustration mit AI erstellt.

Chugai Pharmaceutical (JP3519400000) was quoted at EUR 33.90 at Lang & Schwarz on October 9, 2026 at 12:21 p.m. CEST, down 1.25 percent from the prior close of EUR 34.33. The latest analyst signal came on October 7, 2026, when Citi maintained a Buy rating and set a JPY 11,100.00 price target, according to Markets Insider.

Target meets resilient earnings

The target call followed Chugai's second-quarter results. Revenue reached JPY 341.58 billion in the quarter ended June 30, 2026, compared with JPY 290.01 billion a year earlier, while net profit rose to JPY 116.33 billion from JPY 97.16 billion, Markets Insider reported on October 7, 2026.

The half-year picture was also higher year over year. Chugai reported JPY 663.331 billion in revenue for the six months ended June 30, 2026, compared with JPY 578.463 billion a year earlier, and net income of JPY 231.749 billion versus JPY 194.389 billion, according to JPX Market Explorer.

What does the pipeline reset mean?

On September 28, 2026, Chugai said Roche would discontinue obesity development of emugrobart, also known as GYM329, and return the rights. Chugai began preparations for a Phase III study in spinal muscular atrophy after a Phase II assessment found that clinically meaningful weight loss was unlikely, according to the company's Chugai Pharmaceutical release. The company said the move left its fiscal 2026 consolidated forecast unchanged.

Three dated milestones

On July 25, 2026, Chugai reported half-year revenue of JPY 663.331 billion and net income of JPY 231.749 billion, according to JPX Market Explorer. On September 28, 2026, it returned emugrobart rights and began preparing a spinal muscular atrophy program, according to Chugai Pharmaceutical. On October 7, 2026, Citi kept its Buy rating and JPY 11,100.00 target, according to Markets Insider.

Next dates are set

Chugai's investor-relations calendar lists October 27, 2026 at 5:00 p.m. JST for fiscal 2026 third-quarter results and October 27, 2026 at 6:00 p.m. JST for the results conference, according to Chugai Pharmaceutical.

Tokyo shares remain below the yearly high

On the Tokyo Stock Exchange, Chugai was last quoted at JPY 6,012 on October 9, 2026 at 2:57 p.m. JST, against a 52-week range of JPY 5,974.00 to JPY 10,700.00. The Lang & Schwarz price was EUR 33.90 at 12:21 p.m. CEST on October 9, 2026, down 1.25 percent versus its EUR 34.33 prior close. The further course of trading is shown by the continuously updated real-time quote of Chugai Pharmaceutical stock.